Maternal heterozygous familial hypercholesterolemia and its consequences for mother and child

Circulation

Volumn 124, Issue 15, 2011, Pages 1599-1601

  Rutherford, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COLESEVELAM; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

CENTRAL NERVOUS SYSTEM DISEASE; CONGENITAL MALFORMATION; DIABETES MELLITUS; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HUMAN; HYPERTENSION; LIMB DEFECT; LOW BIRTH WEIGHT; NONHUMAN; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; SMOKING;

CHILD; CHOLESTEROL, LDL; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREMATURE BIRTH;

EID: 80053973673     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.059311     Document Type: Editorial

References (21)

1. Desoye G, Schweditsch MO, Pfeiffer KP, Zechner R, Kostner GM. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab. 1987;64:704-712. (Pubitemid 17044536)
2. Darmady JM, Postle AD. Lipid metabolism in pregnancy. Br J Obstet Gynaecol. 1982;89:211-215. (Pubitemid 12192923)
3. Catov JM, Bodnar LM, Kip KE, Hubel C, Ness RB, Harger G, Roberts JM. Early pregnancy lipid concentrations and spontaneous preterm birth. Am J Obstet Gynecol. 2007;197:610 e611-e617.
4. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterstol K. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis. 2006;189:451-457. (Pubitemid 44740297)
5. Toleikyte I, Retterstøl K, Leren PT, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011; 124:1606-1614.
6. Jensen HK. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Dan Med Bull. 2002;49:318-345. (Pubitemid 35434532)
7. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115: 1948-1967. (Pubitemid 46598908)
8. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476-488.
9. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(suppl):S172-S177.
10. Betteridge DJ, Broome K, Durrington PN, Hawkins MM, Humphries SE, Mann JI, Miller JP, Neil HA, Thompson GR, Thorogood M; Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis. 1999;142: 105-112. (Pubitemid 28551815)
11. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
12. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29:2625-2633.
13. Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 suppl):S38-S45.
14. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350: 1579-1582. (Pubitemid 38477791)
15. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198-208.
16. Salo P, Viikari J, Hamalainen M, Lapinleimu H, Routi T, Ronnemaa T, Seppanen R, Jokinen E, Valimaki I, Simell O. Serum cholesterol ester fatty acids in 7-and 13-month-old children in a prospective randomized trial of a low-saturated fat, low-cholesterol diet: the STRIP baby project. Special Turku coronary Risk factor Intervention Project for children. Acta Paediatr. 1999;88:505-512. (Pubitemid 29289218)
17. The Writing Group for the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). JAMA. 1995;273:1429-1435.
18. Stein EA. Statins and children: whom do we treat and when? Circulation. 2007;116:594-595. (Pubitemid 47356344)
19. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664-668. (Pubitemid 47356351)
20. McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr. 1997;130:266-273. (Pubitemid 27495163)
21. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92:78-82. (Pubitemid 23188871)